Xiu-Li GUO, Ph.D, Professor
PERSONAL DETAILS
Name: Xiu-li Guo
MD, Ph.D, Professor
Head of Institute of New Drug Pharmocology
ADDRESS:
School of Pharmaceutical Science
Shandong University
No. 44, WenHua Xi Road, Jinan, 250012 P.R. China
Tel/Fax. 086-531-88382490
E-mail: guoxl@sdu.edu.cn
EDUCATION:
2001—2004: PhD. Pharmacology, Ocean University of China, Qingdao, China.
1991—1994: MMedSc. Pharmacology, Shandong Medical University, Jinan, China
1987—1991: BSc. Pharmacy, Shandong Medical University, Jinan, China
PROFESSION EXPERIENCE:
2007.09-Date: Professor in Pharmacology, Head of Institute of New Drug Pharmacology, School of Pharmaceutical Science, Shandong University.
2001.9 - 2007.8: Associate Professor, Department of Pharmacology, School of Pharmaceutical Science, Shandong University.
2006.3 - 2007.3: Visiting Scholar in Liverpool University, UK
1996.9 - 2001.8: Lecturer, Department of Pharmacology, School of Pharmaceutical Science, Shandong University.
1994.9 - 1996.8: Assistant, Department of Pharmacology, School of Pharmaceutical Science, Shandong Medical Univ.
RESEARCH FOUNDING
1. “BCRP monoclonal antibody targeted chitosan NPs co-delivery of miR-34a and doxorubicin to reverse drug resistance in breast cancer” funded by National Science Foundation of China, 2021.1-2023.12, project leader
2. “Active targeting of cancer cells with novel receptor guided polymeric drug carriers”， funded by Shandong University-South Australian University healthy study center, 2020.1-2021.12，project leader
3. “Development of the localized controlled drug-eluting stents for oesophageal/ colorectal cancer treatment”, funded by Shandong University-South Australian University healthy study center, 2019.1-2020.12, project leader
4. “Mechanism of galectin-3 on the metastasis of breast cancer with high MUC1 expression and associated drugs.” funded by National Science Foundation of China, 2014.1-2017.12，project leader
5. “Preclinical drugability study of DLJ14 as a novel anti-tumor resistant reversal agent” funded by Shandong Province Science and Technology Key Project, 2015.1-2017.12, project leader
6. “Development of T-2 Trichothecenes (TypeⅠantitumor biotech drug)” funded by the subtopic of Special innovation of major national pharmaceutical drug research, 2012.1-2015.6, project leader
7. “Targeting prostate cancer cells with receptor guided nanoparticles using docetaxel” funded by Shandong University-South Australian University healthy study center. 2014.1-2015.12, project leader
8. “Multi-targeting reversal activity studies of the novel stilbene derivatives containing Ligustrazinyl group on tumor multi-drug resistance”, funded by National Science Foundation of China, 2010.1-2012.12, project leader
9. “Study on anti-vascular dementia effects and molecular mechanism of Ligustrazine derivatives”, funded by National Science Foundation of China, 2007.1-2009.12, project leader
10. “The role of PTEN gene in AngⅡ induced vascular smooth muscle cell proliferation and migration”, funded by Shandong Province Outstanding Young Scientists Research Award Fund Project, 2010.1-2012.12, project leader
11. “Relation of PTEN expression and activity and angiotensinⅡinduces proliferation and migration of vascular smooth muscle cells.”, funded by Science Foundation of Shandong University, 2010.1-2012.12, project leader
RECENT PUBLICATION (2010-date)
1. Xiong Wang, Li Ma, Qiao-yan Ding, Yong-gang Chen, Jun-hua Meng, Jin-hu Wu, Hong-feng Zhang, Xiu-li Guo*. Mircoglial NLRP3 inflammasome activation-mediated inflammation promotes prolactinomas development. Endocr Relat Cancer. 2021, 28(7): 433-448
2. Xiao-xia Yang, Peng-fei Shang, Bing-fang Yu, Qiu-yang Jin, Jing Liao, Lei Wang, Jian-bo Ji, Xiu-li Guo*. Combination therapy with miR34a and doxorubicin synergistically inhibit DOX-resistance breast cancer progression via downregulation of Snail through suppressing Notch/NF-κB and Ras/Raf/MEK/ERK signaling pathway. Acta Pharmaceutica Sinica B. 2021
3. Paris Fouladian, Qiuyang Jin, Mohammad Arafat, Yunmei Song, Xiuli Guo*, Anton Blencowe*, Sanjay Garg*. Drug-loaded, polyurethane coated nitinol stents for the controlled release of Docetaxel for the treatment of Oesophageal cancer. Pharmaceuticals. 2021, 14: 311.
4. Qiu-Yang Jin, Ying-Shuang Li, Xing-Hui Qiao, Jia-Wei Yang, Xiu-Li Guo*. Targeting galectins in T cell-based immunotherapy within tumor microenvironment. Life Sci. 2021, 277: 119426
5. Yi-Fan Dang, Shao-Hui Yang, Xiao-Ning Jiang, Fu-Lian Gong, Xiao-Xia Yang, Yan-Na Cheng, Xiu-Li Guo*. Commination treatment strategies with a focus on rosiglitazone and adriamycin for insulin resistant liver cancer. J Drug Targeting. 2021, 29 (3): 336-348
6. Lin Zhao, Hongyuan Chen, Lu Lu, Chunqian Zhao, Christina V. Malichewe, Lei Wang, Xiuli Guo*, Xinke Zhang*. Design and screening of a novel neuropilin-1 targeted penetrating peptide for anti-angiogenic therapy in glioma. Life Sci. 2021, 270:119113
7. Lin Zhao, Hongyuan Chen, Lu Lu, Lei Wang, Xinke Zhang*, Xiuli Guo*. New insights into the role of co-receptor neuropilins in tumor angiogenesis and lymphangiogenesis and targeted therapy strategies. J Drug Targeting. 2020, 29(2): 155-167.
8. Lei Wang, Ying-Shuang Li, Lu-Gang Yu, Xin-Ke Zhang, Lin Zhao, Fu-Lian Gong, Xiao-Xia Yang, Xiu-Li Guo*. Galectin-3 expression and secretion by tumor-associated macrophages in hypoxia promotes breast cancer progression. Biochem Pharmacol. 2020, 178:114113.
9. Zhao-Yu Shi, Xiao-Xia Yang, ChristinaYallen Malichewe, Ying-Shuang Li, Xiu-Li Guo*. Exosomal miRNAs-mediated intercellular communication and exosome-based cancer treatment. Int J Biol Macromol. 2020, 158: 530-541.
10. Xiao-Tong Li, Ying-Shuang Li, Zhao-Yu Shi, Xiu-Li Guo*. New insights into molecular chaperone TRAP1 as a feasible target for future cancer treatments. Life Sci. 2020, 254: 117737.
11. Fu-Lian Gong, Lei Wang, Lu-Gang Yu, Yi-Fan Dang, Xiao-Ning Jiang, Lin Zhao, Xiu-Li Guo*. DHPAC, a novel microtubule depolymerizing agent, suppresses angiogenesis and vasculogenic mimicry formation of human non-small cell lung cancer. J Cellu Biochem. 2020, 121:4756-4771
12. Ying-Shuang Li, Xiao-Tong Li, Lu-Gang Yu, Lei Wang, Zhao-Yu Shi, Xiu-Li Guo*. Roles of galectin-3 in metabolic disorders and tumor cell metabolism. Int J Biol Macromol. 2020, 142: 463-473.
13. Zhen-Ning Lu, Zhao-Yu Shi, Yi-Fan Dang, Yan-Na Cheng, Yan-Hui Guan, Zhao-Jun Hao, Bing Tian, Hong-Wei He*, Xiu-Li Guo*. Pantoprazole pretreatment elevates sensitization to vincristine in drug-resistant oral epidermoid carcinoma in vitro and in vivo. Biomed Pharmacother. 2019, 120: 109478.
14. Xiao-Xia Yang, Chao Sun, Lei Wang, Xiu-Li Guo*. New insight into isolation, identification techniques and medical applications of exosomes. J Control Release. 2019, 308: 119-129.
15. Xiaoxia Yang, Yongfang Zhang, Christina Malichewe, Zhaoyu Shi, Lei Wang, Zhenning Lu, Xiuli Guo*. Chitosan nanoparticle mediated upregulation of microRNA34a expression to suppress the proliferation, migration, invasion of MDA-MB-231 cells. J Drug Deliv Sci Technol. 2019, 52: 1061-1069.
16. Xiao-Ning Jiang, Yi-Fan Dang, Fu-Lian Gong, Xiu-Li Guo*. Role and regulation mechanism of galectin-3 in non-small cell lung cancer and its potential clinical therapeutic significance. Chem Biol Interact. 2019, 309: 108724.
17. Chao Sun, Lei Wang, Xiao-Xia Yang, Yu-Hua Jiang, Xiu-Li Guo*. The aberrant expression or disruption of desmocollin2 in human diseases. Int J Biol Macromol. 2019, 131: 378-386.
18. Lu-Ning Li, Lei Wang, Yan-Na Cheng, Zhan-Qi Cao, Xin-Ke Zhang, Xiu-Li Guo*. Discovery and characterization of 4-hydroxy-2-pyridone derivative sambutoxin as a potent and promising anticancer drug candidate: activity and molecular mechanism. Mol Pharm. 2018, 15(11): 4898-4911.
19. Zhan-Qi Cao#, Zhao-Jun Hao#, Ming Xin, Lu-Gang Yu, Lei Wang, Ying Zhang, Xin-Ke Zhang, Xiu-Li Guo*. Endogenous and exogenous galectin-3 promote the adhesion of tumor cells with low expression of MUC1 to HUVECs through upregulating N-cadherin and CD44. Lab Invest. 2018, 98 (12): 1642-1656.
20. Hui-Hui Zhang, Ying Zhang, Yan-Na Cheng, Fu-Lian Gong, Zhan-Qi Cao, Lu-Gang Yu, Xiu-Li Guo*. Metformin incombination with curcumin inhibits the growth, metastasis and angiogenesis of hepatocellular carcinoma in vitro and in vivo. Mol Carcinog. 2018, 57: 44-56.
21. Yi-Fan Dang, Xiao-Ning Jiang, Fu-Lian Gong, Xiu-Li Guo*. New insights into molecular mechanisms of rosiglitazone in monotherapy or combination therapy against cancers. Chem Biol Interact. 2018, 296: 162-170.
22. Bing Tian, Zhen-Ning Lu, Xiu-Li Guo*. Regulation and role of nuclear factor-E2-related factor2 (Nrf2) in multidrug resistance of hepatocellular carcinoma. Chem Biol Interact. 2018, 280: 70-76.
23. Ying Zhang, Fu-Lian Gong, Zhen-Ning Lu, Hong-Yuan Wang, Yan-Na Cheng, Zhao-Peng Liu, Lu-Gang Yu, Hui-Hui Zhang, Xiu-Li Guo*. DHPAC, a novel synthetic microtubule destabilizing agent, possess high antitumor activity in vincristine-resistant oral epidermoid carcinoma in vitro and in vivo. Int J Biochem Cell Biol. 2017, 93: 1-11.
24. Ying Zhang, Shao-Hui Yang, Xiu-Li Guo*. New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer. Biomed Pharmacother. 2017, 96:659-666.
25. Zhen-Ning Lu, Bing Tian, Xiu-Li Guo*. Repositioning of proton pump inhibitors in cancer therapy. Cancer Chemother Pharmacol. 2017, 80: 925-937.
26.Yue Zhou, Zhan-Qi Cao, Hong-Yuan Wang, Yan-Na Cheng, Lu-Gang Yu, Xin-Ke Zhang, Yan Sun and Xiu-Li Guo*. The anti-inflammatory effect of Morin hydrate in atherosclerosis is associated with autophagy induction through cAMP signaling. Mol Nutr Food Res, 2017, 61(9).1600966.
27.Yan-Na Liu, Jing-Jing Wang, Ya-Ting Ji, Guo-Dong Zhao, Long-Qian Tang, Cheng-Mei Zhang, Xiu-Li Guo*, Zhao-Peng Liu*. Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazole Analogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site. J Med Chem, 2016, 59 (11): 53 41-55.
28.Hong-Yuan Wang, Ying Zhang, Yue Zhou, Yu-Yin Lu, Wen-Fang Wang, Ming Xin, Xiu-Li Guo*. Rosiglitazone elevates sensitization of drug-resistant oral epidermoid carcinoma cells to vincristine by G2/M-phase arrest, independent of PPAR-γ pathway. Biomed Pharmacother. 2016, 83:349-361.
29. Zhan-Qi Cao, Xiu-Li Guo*. The role of galectin-4 in physiology and diseases. Protein Cell 2016, 7(5): 314-325.
30. Hui-Hui Zhang, Xiu-Li Guo*. Combinational Strategies of Metformin and Chemotherapy in Cancers. Cancer Chemother Pharmacol., 2016, 78(1):13-26.
31.Lei Wang, Xiu-Li Guo*. Molecular regulation of galectin-3 expression and therapeutic implication in cancer progression. Biomed Pharmacother. 2016, 78: 165-171.
